Independence Blue CrossCommercial · Administrative · Pharmacy · PA · Ophthalmology, PharmacyLow impact
08.01.44c, Voretigene Neparvovec-rzyl (Luxturna®)
Effective date
Not stated in the notice
Identified
Jun 19, 2026
Summary
This is a reissue with no substantive changes to Independence Blue Cross Commercial Medical Policy 08.01.44c for voretigene neparvovec-rzyl (Luxturna). The policy maintains existing coverage criteria for RPE65 mutation-associated retinal dystrophy treatment and continues to use HCPCS code J3398. No billing workflow changes are required.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.